Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination.
Apolipoprotein E (apo E) is synthesized and released in greatly increased amounts by peripheral nerve following Wallerian degeneration; it has been suggested that this protein may function in the transport of degenerated myelin lipid. The purpose of this study was to determine if the amount of apo E released by rat peripheral nerve is increased following selective demyelination, in the absence of significant axonopathy. Using an immunoturbidimetric assay, release of apo E from excised sciatic nerve segments was measured during the phases of acute demyelination and remyelination caused by tellurium (Te) toxicity, during segmental demyelination in chronic lead (Pb) poisoning, and during Wallerian degeneration following nerve crush. Morphologic changes were examined in contralateral sciatic nerves by nerve-fiber teasing or by light and electron microscopy of transverse sections. As in previous studies, the amount of apo E released from the nerves was greatly increased following Wallerian degeneration due to nerve crush. In Te neuropathy, increased release of apo E was first detected on the fourth day of Te exposure, corresponding temporally to the acute onset of paralysis and segmental demyelination. Apolipoprotein E release rose steeply to a maximum of ten times the control values by day 9 and then gradually waned during the next five weeks, corresponding to a period of active remyelination and resolution of the neuropathy. In the demyelinating neuropathy of chronic lead poisoning, apo E release was increased four times over control animals after seven weeks of exposure, with less than 10% of teased fibers showing early paranodal demyelination and no evidence of remyelination.(ABSTRACT TRUNCATED AT 250 WORDS)
Gelman
B B
BB
Department of Pathology and Laboratory Medicine, University of North Carolina, School of Medicine, Chapel Hill 27514.
Rifai
N
N
Goodrum
J F
JF
Bouldin
T W
TW
Krigman
M R
MR
D000818:Animals; D001057:Apolipoproteins E / Q000493:pharmacokinetics*; D003711:Demyelinating Diseases / Q000378:metabolism* / Q000473:pathology; D009186:Myelin Sheath / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D012584:Sciatic Nerve / Q000378:metabolism* / Q000473:pathology / Q000502:physiology; D014855:Wallerian Degeneration
D001057:Apolipoproteins E